Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) FCF Margin (2016 - 2025)

Heron Therapeutics' FCF Margin history spans 12 years, with the latest figure at 22.63% for Q4 2025.

  • For Q4 2025, FCF Margin rose 782.0% year-over-year to 22.63%; the TTM value through Dec 2025 reached 18.02%, down 166.0%, while the annual FY2025 figure was 18.02%, 122.0% down from the prior year.
  • FCF Margin reached 22.63% in Q4 2025 per HRTX's latest filing, down from 3.48% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 8.96% in Q3 2024 to a low of 282.08% in Q2 2021.
  • Average FCF Margin over 5 years is 92.2%, with a median of 58.28% recorded in 2023.
  • Peak YoY movement for FCF Margin: crashed -7220bps in 2021, then skyrocketed 17822bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 221.0% in 2021, then soared by 43bps to 126.38% in 2022, then soared by 105bps to 6.44% in 2023, then plummeted by -573bps to 30.45% in 2024, then grew by 26bps to 22.63% in 2025.
  • Per Business Quant, the three most recent readings for HRTX's FCF Margin are 22.63% (Q4 2025), 3.48% (Q3 2025), and 29.77% (Q2 2025).